U.S. markets close in 3 hours 50 minutes
  • S&P 500

    -0.73 (-0.01%)
  • Dow 30

    -171.04 (-0.44%)
  • Nasdaq

    +41.33 (+0.26%)
  • Russell 2000

    +27.57 (+1.36%)
  • Crude Oil

    +0.74 (+0.95%)
  • Gold

    +3.30 (+0.16%)
  • Silver

    -0.01 (-0.03%)

    +0.0002 (+0.02%)
  • 10-Yr Bond

    -0.0060 (-0.14%)

    +0.0001 (+0.01%)

    -0.1610 (-0.11%)
  • Bitcoin USD

    +3,752.27 (+7.03%)
  • CMC Crypto 200

    0.00 (0.00%)
  • FTSE 100

    -1.28 (-0.02%)
  • Nikkei 225

    +5.81 (+0.01%)

Halberd's CEO on The Stock Day Podcast Breaking Down 20X Neutralizing Affinity SARS-COV-2 Antibody

Phoenix, Arizona--(Newsfile Corp. - March 9, 2021) - The Stock Day Podcast welcomed Halberd Corporation (OTC Pink: HALB) ("the Company"), a company that holds the exclusive rights to the patented extracorporeal treatment technology and the provisional patent applications associated with COVID-19. CEO and Chairman of the Company, William A Hartman, joined Stock Day host Everett Jolly.

Jolly began the interview by commenting on a recent announcement regarding the Company's proprietary monoclonal antibody against the SARS-COV-2 Spike protein, which demonstrated 20 times greater neutralizing affinity compared to their original antibody. Hartman elaborated on the significance of the Company's announcement, which detailed the antibody's ability to target both the S-protein and N-protein. "We're letting the world know what we have accomplished, both the investing community as well as competitors and potential partners," explained Hartman.

"Why are partnerships so important to Halberd Corporation?" asked Jolly. "In order to bring any product forward that requires FDA approval, you're talking about millions of dollars and potentially several years. You can shorten that with an Emergency Use Authorization (EUA)," said Hartman, adding that the Company is working to get qualified for an EUA. "However, even with the EUA, it will take millions of dollars. We're a small company, it would be easier if we were able to spread that financial requirement around with a Big Pharma partner."

Hartman then shared that whether or not the Company is able to partner with a Big Pharma company, it will continue to develop its patent pending radio frequency technology designed to eliminate disease pathogens. "We have partnered with a company by the name of 'GreenBioAZ'," he shared. "They're part of the incubator out of Arizona State University."

"Why are you so excited about this project going forward?" asked Jolly. "We're starting with E. coli," shared Hartman. "If you eliminate E. coli from cerebral spinal fluid, you're eliminating meningitis," he continued. "If you eliminate E. coli from blood, you're eliminating blood sepsis, which kills almost 270,000 people each year," said Hartman. "We are starting with E. coli because we can do all of this experimentation in a regular laboratory and not a Level-three laboratory that would be required for dealing with COVID."

"We're going to work our way towards working with COVID, where we already have a much stronger antibody," continued Hartman. "The bottom line is that we've already acquired a lot of the equipment and supplies required for the RF project. So, this Radio Frequency project is huge and could revolutionize medicine! It may eliminate virtually all diseases, whether the medium is spinal fluid or blood."

"Are you still pursuing the immune booster vitamin?" asked Jolly. "Introducing an immune booster vitamin is a big deal," said Hartman. "We basically planned on three different varieties, including a vanilla variety, a max version, and a super max version that would be sold only via prescription. However, the final version would require FDA approval, and we are trying to eliminate any delays," he explained. "So, we're going to come out with one version, a max version," shared Hartman. "I think we're probably going to be on the market within the month."

"Basically, every one of the ingredients in our MAX Version will be backed by medical articles supporting how each ingredient enforces and upgrades the immune system against COVID-19, as well as general health," said Hartman.

"Do you see the company generating revenues here in the second quarter?" asked Jolly. "Yes," said Hartman. "Halberd is a great investment, simply because we have tremendous technology," he shared, noting that the Company is also in the process of developing additional technologies. "Our extracorporeal radio frequency experimentation is a blockbuster, and we're very excited about it."

To close the interview, Hartman elaborated on the Company's investment potential, especially considering their current valuation and the significance of their proprietary technologies. "Everything we have discussed today, we are actually doing," said Hartman. "Technology will be the driver of our stock," he added. "Halberd is a company where we have a tremendous field of inventors, developers, pharmaceutical representatives, as well as people off-shore in Brazil that are on our Strategic Advisory Board, and we are loaded with PhDs and MDs. I just believe that technology is going to be the driver in the future."

To hear Bill Hartman's entire interview, follow the link to the podcast here:

Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at

About Halberd Corporation.

Halberd Corporation. (OTC Pink: HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Halberd's Articles of Incorporation prohibit the company from issuance of convertible debt which would result in dilution. See the company's Articles of Incorporation here.

The company holds the exclusive rights to the COVID-19 extracorporeal treatment technology provisional patent applications: "Method for Treating and Curing COVID-19 Infection;" "Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients;" "Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus," "Nasal Spray To Prevent The Transmission Of COVID-19 Between Humans," "Nasal Spray to Prevent the Transmission of COVID-19," "Method For Treating And Curing COVID-19 Infection By Utilizing Radiofrequency Extracorporeally To Eradicate The Virus," and "Medication For The Reduction Of Morbidity And Mortality In Persons Infected By Sars-Cov-2 (COVID-19 Virus)." Halberd also holds the exclusive rights to theunderlying granted U.S. Patent 9,216,386 and U.S. Patent 8,758,287.

Safe Harbor Notice

Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.

Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -

On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.

The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment or other strategies with regard to COVID-19.

The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.

We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.

For more information please contact:

William A. Hartman

About The "Stock Day" Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America.


Stock Day Media
(602) 821-1102

To view the source version of this press release, please visit